Concepedia

José Saro

JS

Statistics

Publications

6

Citations

117

H-Index

6

Active since

2008

Affiliations

Roche (Switzerland)(Current)

Institut Gustave Roussy

The Netherlands Cancer Institute

Universidad de Navarra

Hospital Universitario Fundación Jiménez Díaz

José Saro is an author at Roche (Switzerland) specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2008–2024

6

Publications

6

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)

Guillem Argilés, José Saro, Neil H. Segal et al. · Annals of Oncology · 2017 · 28 citations · Full text

, , +17

Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

Neil H. Segal, José Saro, Ignacio Melero et al. · Annals of Oncology · 2017 · 27 citations · Full text

, , +17

TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study

Eric Angevin, James Lopez, A. U. Pande et al. · Journal of Clinical Oncology · 2009 · 22 citations

, , +17

A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma

K. B. Kim, José Saro, Stergios Moschos et al. · Journal of Clinical Oncology · 2008 · 17 citations

, , +15

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters, Eric Angevin, Teresa Alonso‐Gordoa et al. · Clinical Cancer Research · 2024 · 13 citations

, , +17

1–5 of 6